Safety & Efficacy Study of quetiapine fumarate (SEROQUEL®) vs. placebo and active control in Major Depressive Disorder - DIAMOND
Study identifier:D1448C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled and Active-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-release (SEROQUEL®) as Monotherapy in the Treatment of Patients with MDD
Medical condition
Major depressive disorder
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine fumarate, Duloxetine
Sex
All
Actual Enrollment
600
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Apr 2006
Primary Completion Date: -
Study Completion Date: 01 May 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Art Lazarus
AstraZeneca
